{"id":753,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"thymosin-alpha-1-tests-phase-3-sepsis-trial-2025","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","title":{"rendered":"Thymosin Alpha-1 en sepsis: resultado de la fase 2025 TESTS 3"},"content":{"rendered":"

El ensayo 2025 TESTS es m\u00e1s informativo que los peque\u00f1os informes anteriores sobre sepsis: los adultos de 1,106 fueron aleatorizados en los centros de 22, y la timosina alfa-1 no redujo la mortalidad por todas las causas en el d\u00eda de 28.<\/p>

Evidencia de un vistazo<\/h2>
  • El ensayo aleatoriz\u00f3 a adultos 1,106; 1,089 se incluyeron en el an\u00e1lisis por intenci\u00f3n de tratar modificado.<\/li>
  • La mortalidad a los veintiocho d\u00edas fue 23.4% con timosina alfa-1 y 24.1% con placebo.<\/li>
  • El \u00edndice de riesgo fue 0.99 (95% CI 0.77\u20131.27; P = 0.93), y ning\u00fan resultado secundario o de seguridad difiri\u00f3 significativamente.<\/li><\/ul><\/div><\/div>
    \"Visualizaci\u00f3n
    Ilustraci\u00f3n original de investigaci\u00f3n editorial. No es una figura de estudio, una imagen de un paciente, una fotograf\u00eda de un producto, un resultado de ensayo suministrado ni una representaci\u00f3n de un lote de cat\u00e1logo.<\/figcaption><\/figure>

    Registro de estudio<\/h2>

    El criterio de valoraci\u00f3n principal fue la muerte por cualquier causa en los d\u00edas 28. El \u00edndice de riesgo cercano a la unidad y el intervalo de confianza que cruza uno no proporcionan evidencia clara de reducci\u00f3n de la mortalidad en la poblaci\u00f3n general del ensayo.<\/p>

    Dise\u00f1o<\/strong>Fase multic\u00e9ntrica, doble ciego, aleatorizada y controlada con placebo 3<\/span><\/div>
    Sitios<\/strong>Centros 22 en China<\/span><\/div>
    Modificado ITT<\/strong>542 timosina alfa-1; 547 placebo<\/span><\/div>
    Mortalidad en d\u00edas 28<\/strong>23.4% versus 24.1%<\/span><\/div>
    Estimaci\u00f3n del efecto<\/strong>HR 0.99; 95% CI 0.77\u20131.27; P=0.93<\/span><\/div><\/div><\/div>

    Resultados en contexto<\/h2>

    Las interacciones de subgrupos preespecificadas por edad y diabetes generaron posibles se\u00f1ales diferenciales. Los subgrupos son \u00fatiles para dise\u00f1ar estudios futuros, pero no revierten un resultado primario neutral y no deben publicitarse como indicaciones establecidas.<\/p>

    Un metan\u00e1lisis de 2025 agrup\u00f3 los ensayos aleatorios de 11 con participantes de 1,927 y encontr\u00f3 un odds ratio general de 0.73. Sin embargo, sus subconjuntos multic\u00e9ntricos y de alta calidad no fueron estad\u00edsticamente significativos, y el an\u00e1lisis secuencial de los ensayos consider\u00f3 que la muestra disponible era inadecuada. Por lo tanto, el gran resultado TESTS debe estar en el centro de cualquier resumen actual.<\/p>

    Lo que la evidencia no puede establecer<\/h2>

    Es posible que un ensayo nacional no represente todos los sistemas de salud o fenotipos de sepsis.<\/p>

    Los efectos de subgrupo requieren confirmaci\u00f3n y deben seguir generando hip\u00f3tesis.<\/p>

    Un ensayo cl\u00ednico de una intervenci\u00f3n terminada no valida un lote de investigaci\u00f3n no relacionado.<\/p>","protected":false},"excerpt":{"rendered":"

    El ensayo 2025 TESTS es m\u00e1s informativo que los peque\u00f1os informes anteriores sobre sepsis: los adultos de 1,106 fueron aleatorizados en los centros de 22, y la timosina alfa-1 no redujo la mortalidad por todas las causas en el d\u00eda de 28.<\/p>","protected":false},"author":1,"featured_media":737,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"369","pim_article_type":"Published evidence review","pim_evidence_level":"Large multicenter randomized phase 3 human trial with a neutral primary outcome","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"TESTS phase 3 thymosin alpha-1 sepsis trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39814420\/\",\"note\":\"Primary 2025 multicenter trial; PMID 39814420.\"},{\"title\":\"2025 thymosin alpha-1 sepsis meta-analysis\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40969554\/\",\"note\":\"Eleven RCTs with quality and trial-sequential analyses; PMID 40969554.\"},{\"title\":\"PubChem Thymalfasin record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Thymalfasin\",\"note\":\"Sequence, formula, mass and synonym record; CID 16130571.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\nThymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result<\/title>\n<meta name=\"description\" content=\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\" \/>\n<meta property=\"og:description\" content=\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"},\"wordCount\":272,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\",\"name\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Multicenter two-arm sepsis trial data visualization with near-overlapping outcomes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Thymosin Alpha-1 en sepsis: resultado de la fase 2025 TESTS 3","description":"El ensayo 2025 TESTS es m\u00e1s informativo que los peque\u00f1os informes anteriores sobre sepsis: los adultos 1,106 fueron aleatorizados en los centros 22, y la timosina alfa-1 no re...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","og_locale":"es_ES","og_type":"article","og_title":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result","og_description":"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026","og_url":"https:\/\/nhdbio.com\/es\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"wordCount":272,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","url":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","name":"Thymosin Alpha-1 en sepsis: resultado de la fase 2025 TESTS 3","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"El ensayo 2025 TESTS es m\u00e1s informativo que los peque\u00f1os informes anteriores sobre sepsis: los adultos 1,106 fueron aleatorizados en los centros 22, y la timosina alfa-1 no re...","breadcrumb":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Multicenter two-arm sepsis trial data visualization with near-overlapping outcomes"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=753"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/753\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/737"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}